Fabrice Chouraqui describes Cellarity's platform and how it is being put to use for indications such as sickle cell disease and MASH.

CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than others.

Jim Porter describes the chemistry that has led to early stage success against ALK and ROS1.

Mark Valleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once.

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity.

He describes how Fog is leveraging the way α-helices mediate interactions with other proteins to solve the undruggable problem.

Andy Schwab describes founding 5AM in 2002 and discusses portfolio companies Radionetics, Latigo, TMRW, and Skye Bioscience.

Joseph Panetta introduces the conference and we discuss the state of biotech in California's numerous biotech hubs.

He discusses some of the key theme of the conference including obesity, IgG, ATTR cardiomyopathy, and more.

Kevin Parker describes how Cartography has been building an antigen map over previous years.

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, and more.

Raphael Townshend describes how the company has used AI and large language models to understand the structure and function of RNA.

Daphne Koller describes the platform insitro has been building since it was founded in 2018.

David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, and more.

Aaron Kantoff describes Scion's mission and investment strategy and shares his thoughts on the current state of biotech.

The CEO of the Pennsylvania Biotechnology Center, Hepatitis B Foundation, and Blumberg Institute talks about Pennsylvania biotech.

Dr. Grupp describes the factors that might affect access, demand, and the longevity of the launches of the new sickle cell products.

Dr. Levine highlights work being done at UPenn including a 3-day CAR with IL-18, a dual CAR targeting GBM

Jeff Marrazzo describes the strengths that Philadelphia has to make it biotech's capital of cell and gene therapy.

Bassil Dahiyat walks us through the latest advances in bi-specific antibody engineering and gives his take on L.A.'s biotech scene.